Table 3.
The impact of factors other than the RUNX1-RUNX1T1 transcript levels after HSCT on relapse
| Factors | 3-year CIR rate (95% CI) | P value |
|---|---|---|
| WBC count at diagnosis | ||
| ≤ 10 × 109/L | 24.6% (9.1–44.0%) | 0.31 |
| > 10 × 109/L | 17.1% (5.1–35.0%) | |
| c-KIT gene | ||
| Mutation | 38.4% (20.0–56.6%) | 0.003 |
| Wild type | 15.4% (2.4–38.9%) | |
| Karyotype | ||
| Sole t(8;21) | 20.6% (4.3–45.4%) | 0.56 |
| Additional abnormalities | 21.6% (7.6–40.3%) | |
| Course acquired to achieve CR | ||
| 1 | 19.0% (6.1–372%) | 0.20 |
| > 1 | 24.2% (7.9–45.3%) | |
| Time interval from diagnosis to transplant | ||
| < 8 months | 23.5% (9.4–41.2%) | 0.87 |
| ≥ 8 months | 16.4% (4.3–35.5%) | |
| Disease status pre-HSCT | ||
| 1st CR | 18.8% (7.7–33.6%) | 0.071 |
| 2nd CR | 33.3% (9.0–60.4%) | |
| Donor resource | ||
| HLA-matched sibling | 31.4% (13.5–51.2%) | 0.039 |
| Alternative donor | 14.6% (4.2–31.0%) | |
| RUNX1-RUNX1T1 transcript levels pre-HSCT | ||
| ≥ 3-log reduction | 11.1% (0.9–36.4%) | <0.0001 |
| < 3-log reduction | 27.9% (14.6–42.9%) | |
| Acute GVHD | ||
| With | 21.6% (7.5–40.5%) | 0.52 |
| Without | 18.9% (6.0–37.3%) | |
Statistically significant factors are italicized